<?xml version="1.0" encoding="UTF-8"?>
<ref id="B16">
 <label>16.</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Mühlebach</surname>
    <given-names>S</given-names>
   </name>
   <name>
    <surname>Vulto</surname>
    <given-names>A</given-names>
   </name>
   <name>
    <surname>de Vlieger</surname>
    <given-names>JSB</given-names>
   </name>
   <name>
    <surname>Weinstein</surname>
    <given-names>V</given-names>
   </name>
   <name>
    <surname>Flühmann</surname>
    <given-names>B</given-names>
   </name>
   <name>
    <surname>Shah</surname>
    <given-names>VP</given-names>
   </name>
  </person-group>
  <article-title>The authorization of non-biological complex drugs (NBCDs) follow-on versions: specific regulatory and interchangeability rules ahead?</article-title>
  <source>GaBI J</source>. (
  <year>2013</year>) 
  <volume>2</volume>:
  <fpage>204</fpage>–
  <lpage>7</lpage>. 
  <pub-id pub-id-type="doi">10.5639/gabij.2013.0204.054</pub-id>
 </mixed-citation>
</ref>
